$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx

$egrx Overview Financials Valuation SEC Filings Company Website

2015 Q1 Form 10-Q Financial Statement

#000082787115000031 Filed on May 15, 2015

Income Statement

Concept	2015 Q1	2014 Q1
Revenue	$36.31M	$5.005M
YoY Change	625.45%	101.75%
Cost Of Revenue	$5.948M	$3.360M
YoY Change	77.02%	155.88%
Gross Profit	$30.36M	$1.645M
YoY Change	1745.65%	40.88%
Gross Profit Margin	83.62%	32.87%
Selling, General & Admin	$3.986M	$1.454M
YoY Change	174.14%	-50.69%
% of Gross Profit	13.13%	88.39%
Research & Development	$6.285M	$3.794M
YoY Change	65.66%	50.26%
% of Gross Profit	20.7%	230.64%
Depreciation & Amortization	$12.00K	$29.00K
YoY Change	-58.62%
% of Gross Profit	0.04%	1.76%
Operating Expenses	$16.22M	$8.608M
YoY Change	88.42%	26.83%
Operating Profit	$20.09M	-$3.603M
YoY Change	-657.59%	-16.33%
Interest Expense	$1.000K	$1.000K
YoY Change	0.0%	-99.31%
% of Operating Profit	0.0%
Other Income/Expense, Net	$6.000K	-$376.0K
YoY Change	-101.6%	-24.46%
Pretax Income	$20.10M	-$3.979M
YoY Change	-605.05%	-17.17%
Income Tax	$399.0K	-$1.295M
% Of Pretax Income	1.99%
Net Earnings	$19.70M	-$2.684M
YoY Change	-833.87%	-44.13%
Net Earnings / Revenue	54.25%	-53.63%
Basic Earnings Per Share	$1.38	-$0.36
Diluted Earnings Per Share	$1.31	-$0.36
COMMON SHARES
Basic Shares Outstanding	14.25M shares	8.862M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q1	2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$115.9M	$54.90M
YoY Change	111.11%
Cash & Equivalents	$99.92M	$54.88M
Short-Term Investments	$16.00M
Other Short-Term Assets	$174.0K	$212.1K
YoY Change	-17.94%
Inventory	$2.018M
Prepaid Expenses
Receivables	$10.51M	$7.820M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$129.8M	$63.53M
YoY Change	104.29%
LONG-TERM ASSETS
Property, Plant & Equipment	$100.0K	$377.5K
YoY Change	-73.51%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$45.00K	$45.00K
YoY Change	0.0%
Total Long-Term Assets	$145.0K	$422.5K
YoY Change	-65.68%
TOTAL ASSETS
Total Short-Term Assets	$129.8M	$63.53M
Total Long-Term Assets	$145.0K	$422.5K
Total Assets	$129.9M	$63.96M
YoY Change	103.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.435M	$2.458M
YoY Change	121.09%
Accrued Expenses	$15.03M	$7.116M
YoY Change	111.21%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$27.05M	$19.27M
YoY Change	40.38%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities		$0.00
YoY Change
Total Long-Term Liabilities	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$27.05M	$19.27M
Total Long-Term Liabilities	$0.00	$0.00
Total Liabilities	$27.00M	$19.30M
YoY Change	39.9%
SHAREHOLDERS EQUITY
Retained Earnings	-$89.99M	-$92.14M
YoY Change	-2.34%
Common Stock	$15.00K	$14.02K
YoY Change	6.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$102.9M	$44.69M
YoY Change
Total Liabilities & Shareholders Equity	$129.9M	$63.96M
YoY Change	103.16%

Cashflow Statement

Concept	2015 Q1	2014 Q1
OPERATING ACTIVITIES
Net Income	$19.70M	-$2.684M
YoY Change	-833.87%	-44.13%
Depreciation, Depletion And Amortization	$12.00K	$29.00K
YoY Change	-58.62%
Cash From Operating Activities	$25.84M	-$2.071M
YoY Change	-1347.51%
INVESTING ACTIVITIES
Capital Expenditures	$43.00K	$28.00K
YoY Change	53.57%
Acquisitions
YoY Change
Other Investing Activities	-$36.00M	$0.00
YoY Change
Cash From Investing Activities	-$16.04M	-$28.00K
YoY Change	57189.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$54.70M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$55.26M	$47.01M
YoY Change	17.56%
NET CHANGE
Cash From Operating Activities	$25.84M	-$2.071M
Cash From Investing Activities	-$16.04M	-$28.00K
Cash From Financing Activities	$55.26M	$47.01M
Net Change In Cash	$65.06M	$44.91M
YoY Change	44.87%
FREE CASH FLOW
Cash From Operating Activities	$25.84M	-$2.071M
Capital Expenditures	$43.00K	$28.00K
Free Cash Flow	$25.79M	-$2.099M
YoY Change	-1328.82%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q4	egrx	Prepaid Product Costs PrepaidProductCosts	1020000	USD
CY2015Q1	egrx	Prepaid Product Costs PrepaidProductCosts	321000	USD
CY2015Q1	dei	Amendment Flag AmendmentFlag	false
CY2015Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2015Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015Q1	dei	Document Period End Date DocumentPeriodEndDate	2015-03-31
CY2015Q1	dei	Document Type DocumentType	10-Q
CY2015Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000827871
CY2015Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	15538943	shares
CY2015Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2015Q1	dei	Entity Registrant Name EntityRegistrantName	EAGLE PHARMACEUTICALS, INC.
CY2014Q4	egrx	Accrued Product Costs Current AccruedProductCostsCurrent	839000	USD
CY2015Q1	egrx	Accrued Product Costs Current AccruedProductCostsCurrent	1363000	USD
CY2014Q4	egrx	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	1307000	USD
CY2015Q1	egrx	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	1031000	USD
CY2014Q1	egrx	Accrued Stock Issuance Costs AccruedStockIssuanceCosts	0	USD
CY2015Q1	egrx	Accrued Stock Issuance Costs AccruedStockIssuanceCosts	365000	USD
CY2014Q1	egrx	Deferred Ipo Costs DeferredIPOCosts	-1000	USD
CY2015Q1	egrx	Deferred Ipo Costs DeferredIPOCosts	0	USD
CY2014Q1	egrx	Income Taxes Paid Franchise Taxes Paid IncomeTaxesPaidFranchiseTaxesPaid	8000	USD
CY2015Q1	egrx	Income Taxes Paid Franchise Taxes Paid IncomeTaxesPaidFranchiseTaxesPaid	53000	USD
CY2014Q1	egrx	Increase Decreasein Prepaid Expenseand Other Current Assets Total IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal	464000	USD
CY2015Q1	egrx	Increase Decreasein Prepaid Expenseand Other Current Assets Total IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal	-300000	USD
CY2015Q1	egrx	Maximum Expected Cash Proceeds On Additional Milestones MaximumExpectedCashProceedsOnAdditionalMilestones	90000000	USD
CY2014Q4	egrx	Prepaid Equipment PrepaidEquipment	0	USD
CY2015Q1	egrx	Prepaid Equipment PrepaidEquipment	118000	USD
CY2014Q4	egrx	Prepaid Fda User Fee PrepaidFDAUserFee	148000	USD
CY2015Q1	egrx	Prepaid Fda User Fee PrepaidFDAUserFee	99000	USD
CY2015Q1	egrx	Royalty Revenue Commercial Partners Obligationof Sales Report Term RoyaltyRevenueCommercialPartnersObligationofSalesReportTerm	P60D
CY2014Q1	egrx	Stock Issued During Period Shares Warrants Exercised StockIssuedDuringPeriodSharesWarrantsExercised	1788	shares
CY2015Q1	egrx	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	564000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3501000	USD
CY2015Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	5435000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11956000	USD
CY2015Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10508000	USD
CY2014Q4	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	0	USD
CY2015Q1	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	399000	USD
CY2014Q4	us-gaap	Accrued Insurance Current And Noncurrent AccruedInsuranceCurrentAndNoncurrent	0	USD
CY2015Q1	us-gaap	Accrued Insurance Current And Noncurrent AccruedInsuranceCurrentAndNoncurrent	421000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12165000	USD
CY2015Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15029000	USD
CY2014Q4	us-gaap	Accrued Payroll Taxes Current And Noncurrent AccruedPayrollTaxesCurrentAndNoncurrent	0	USD
CY2015Q1	us-gaap	Accrued Payroll Taxes Current And Noncurrent AccruedPayrollTaxesCurrentAndNoncurrent	809000	USD
CY2014Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	502000	USD
CY2015Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	537000	USD
CY2014Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1025000	USD
CY2015Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	733000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	137577000	USD
CY2015Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	192855000	USD
CY2015Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	384000	USD
CY2014Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	284000	USD
CY2015Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	384000	USD
CY2015Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2014Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4404189	shares
CY2015Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	118619	shares
CY2014Q4	us-gaap	Assets Assets	50094000	USD
CY2015Q1	us-gaap	Assets Assets	129933000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	49707000	USD
CY2015Q1	us-gaap	Assets Current AssetsCurrent	129788000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9974000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54880000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34869000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	99924000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	44906000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	65055000	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	974311	shares
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2014Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	USD
CY2015Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	15998000	USD
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14036680	shares
CY2015Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15509179	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14036680	shares
CY2015Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15509179	shares
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	14000	USD
CY2015Q1	us-gaap	Common Stock Value CommonStockValue	15000	USD
CY2014Q1	us-gaap	Cost Of Revenue CostOfRevenue	3360000	USD
CY2015Q1	us-gaap	Cost Of Revenue CostOfRevenue	5948000	USD
CY2014Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	414000	USD
CY2015Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	6520000	USD
CY2015Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	6585000	USD
CY2014Q1	us-gaap	Depreciation Depreciation	29000	USD
CY2015Q1	us-gaap	Depreciation Depreciation	12000	USD
CY2014Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
CY2015Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.38
CY2014Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.36
CY2015Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.31
CY2014Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	383000	USD
CY2015Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2014Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2015Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-273000	USD
CY2014Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3979000	USD
CY2015Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	20096000	USD
CY2014Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1295000	USD
CY2015Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	399000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	112000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1884000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1228000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1448000	USD
CY2014Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1965000	USD
CY2015Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2549000	USD
CY2014Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-325000	USD
CY2015Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	65000	USD
CY2014Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
CY2015Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	776000	USD
CY2014Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-1000	USD
CY2015Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
CY2014Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2015Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	793992	shares
CY2014Q1	us-gaap	Interest Expense InterestExpense	1000	USD
CY2015Q1	us-gaap	Interest Expense InterestExpense	1000	USD
CY2014Q1	us-gaap	Interest Paid InterestPaid	1000	USD
CY2015Q1	us-gaap	Interest Paid InterestPaid	1000	USD
CY2014Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1242000	USD
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2015Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	604000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	1242000	USD
CY2015Q1	us-gaap	Inventory Net InventoryNet	2018000	USD
CY2014Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	0	USD
CY2015Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	1414000	USD
CY2015Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	1400000	USD
CY2015Q1	us-gaap	Inventory Write Down InventoryWriteDown	1100000	USD
CY2014Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	8000	USD
CY2015Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	7000	USD
CY2014Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	72000	USD
CY2015Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	68000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	50094000	USD
CY2015Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	129933000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22186000	USD
CY2015Q1	us-gaap	Liabilities Current LiabilitiesCurrent	27049000	USD
CY2015Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	959000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	47005000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	55260000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-28000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-16041000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2071000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	25836000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-2684000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	19697000	USD
CY2014Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3218000	USD
CY2015Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	19697000	USD
CY2014Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-3218000	USD
CY2015Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	19697000	USD
CY2014Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-376000	USD
CY2015Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6000	USD
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	8608000	USD
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	16219000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3603000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	20090000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	45000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	304000	USD
CY2015Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	274000	USD
CY2014Q4	us-gaap	Other Assets Current OtherAssetsCurrent	289000	USD
CY2015Q1	us-gaap	Other Assets Current OtherAssetsCurrent	174000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	45000	USD
CY2015Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	45000	USD
CY2014Q1	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	265000	USD
CY2015Q1	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	30000000	USD
CY2014Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	5158000	USD
CY2015Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	28000	USD
CY2015Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	43000	USD
CY2015Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1640000	USD
CY2015Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1340000	USD
CY2014Q4	us-gaap	Prepaid Insurance PrepaidInsurance	183000	USD
CY2015Q1	us-gaap	Prepaid Insurance PrepaidInsurance	628000	USD
CY2014Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	46069000	USD
CY2015Q1	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived	30000000	USD
CY2014Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2015Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	564000	USD
CY2014Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	21000	USD
CY2014Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	21000	USD
CY2015Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	342000	USD
CY2015Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	100000	USD
CY2015Q1	us-gaap	Purchase Obligation PurchaseObligation	4535000	USD
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3794000	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6285000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-109683000	USD
CY2015Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-89986000	USD
CY2014Q1	us-gaap	Royalty Revenue RoyaltyRevenue	3565000	USD
CY2015Q1	us-gaap	Royalty Revenue RoyaltyRevenue	3253000	USD
CY2014Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1175000	USD
CY2015Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	3056000	USD
CY2014Q1	us-gaap	Sales Revenue Net SalesRevenueNet	5005000	USD
CY2015Q1	us-gaap	Sales Revenue Net SalesRevenueNet	36309000	USD
CY2014Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1454000	USD
CY2015Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3986000	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	140000	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	384000	USD
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.6400
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.3038
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0825
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0192
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0175
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0163
CY2014Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2015Q1	us-gaap	Short Term Investments ShortTermInvestments	15998000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	27908000	USD
CY2015Q1	us-gaap	Stockholders Equity StockholdersEquity	102884000	USD
CY2014Q1	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	534000	USD
CY2015Q1	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	0	USD
CY2014Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	8862212	shares
CY2015Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	15041011	shares
CY2014Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8862212	shares
CY2015Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14247019	shares
CY2015Q1	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Interim Condensed Financial Statements</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited interim condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for reporting on Form 10-Q. Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary for the fair presentation of the financial information for the interim periods reported have been made. Results of operations for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">March 31, 2015</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results for the year ending December 31, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2015</font><font style="font-family:inherit;font-size:10pt;"> or any period thereafter. These unaudited interim condensed financial statements should be read in conjunction with the audited financial statements and related notes included in our annual report on Form 10-K for the fiscal year ended September 30, 2014, filed with the Securities and Exchange Commission on December 22, 2014.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 20, 2015, the Board of Directors of the Company authorized a change in the Company’s fiscal year end from September 30</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:10pt;"> to December 31</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">st</sup></font><font style="font-family:inherit;font-size:10pt;">.  The change was intended to better align the Company’s fiscal year with the business cycles of other specialty pharmaceutical companies. As a result of the change in fiscal year, the Company’s 2015 fiscal year began on January 1, 2015 and will end on December 31, 2015.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the change in fiscal year, on February 17, 2015 the Company filed a Transition Report on Form 10-Q covering the transition period from October 1, 2014 to December 31, 2014.</font></div></div>
CY2015Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements including disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. The Company's critical accounting policies are those that are both most important to the Company's financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0000827871-15-000031-index-headers.html	Edgar Link	pending
0000827871-15-000031-index.html	Edgar Link	pending
0000827871-15-000031.txt	Edgar Link	pending
0000827871-15-000031-xbrl.zip	Edgar Link	pending
doc_116842003xvx2xcephalon.htm	Edgar Link	pending
doc_116846672xvx2xcephalon.htm	Edgar Link	pending
egrx-20150331.xml	Edgar Link	completed
egrx-20150331.xsd	Edgar Link	pending
egrx-20150331_cal.xml	Edgar Link	unprocessable
egrx-20150331_def.xml	Edgar Link	unprocessable
egrx-20150331_lab.xml	Edgar Link	unprocessable
egrx-20150331_pre.xml	Edgar Link	unprocessable
egrx_q1x2015new.htm	Edgar Link	pending
exhibit311q12015new.htm	Edgar Link	pending
exhibit312q12015new.htm	Edgar Link	pending
exhibit321q12015new.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx

2015 Q1 Form 10-Q Financial Statement

#000082787115000031 Filed on May 15, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EGRX EAGLE PHARMACEUTICALS, INC. Stock $egrx

2015 Q1 Form 10-Q Financial Statement

#000082787115000031 Filed on May 15, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx